Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel
OTCMKTS:BICX

Biocorrx Q4 2025 Earnings Report

Biocorrx logo
$0.21 +0.01 (+5.47%)
As of 10:02 AM Eastern
ProfileEarnings History

Biocorrx EPS Results

Actual EPS
$0.05
Consensus EPS
-$0.06
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Biocorrx Revenue Results

Actual Revenue
($0.15) million
Expected Revenue
$0.22 million
Beat/Miss
Missed by -$370.00 thousand
YoY Revenue Growth
N/A

Biocorrx Announcement Details

Quarter
Q4 2025
Date
3/31/2026
Time
During Market Hours
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Biocorrx's next earnings date is estimated for Tuesday, November 17, 2026, based on past reporting schedules.

Conference Call Resources

Biocorrx Earnings Headlines

Biocorrx Inc. (OTCMKTS:BICX) Stock Short Interest Drops 44.3%
September 30 at 2:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31067403
BioCorRx Inc. Appoints Former Acting White House Drug Policy Director Richard J. Baum to Strategic Advisory Board
September 10, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biocorrx-inc-appoints-former-acting-091600940.html
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.tc pixel
October 1 at 1:00 AM  |  Investors Alley (Ad)
BioCorRx Announces National Drug Codes (NDCs) for LUCEMYRA (lofexidine) Brand and Authorized Generic (AG) SKUs to Ensure Uninterrupted Market Supply
August 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/biocorrx-announces-national-drug-codes-121700855.html
BioCorRx Inc.
April 21, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/Stock/BICX/financials
BioCorRx, Inc. Announces Issuance of U.S. Patent Supporting Its Biodegradable Naltrexone Implant Technology
March 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/news/biocorrx-inc-announces-issuance-u-123000683.html
See More Biocorrx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biocorrx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biocorrx and other key companies, straight to your email.

About Biocorrx

Biocorrx (OTCMKTS:BICX) develops addiction treatment programs and related products designed to support individuals seeking recovery from alcohol and substance use disorders. The company’s offerings include the BioCorRx Recovery Program, which combines an initial detoxification protocol with counseling, behavioral support and ongoing recovery services. BioCorRx describes the program as non-addictive and designed to be delivered through qualified treatment providers.

The company also develops and markets nutritional supplements intended to support recovery and help address cravings and related wellness needs. Its product portfolio has included the UnBuzzed line and other supplements associated with alcohol-recovery support. BioCorRx licenses its recovery program and related intellectual property to independent providers, allowing treatment centers and practitioners to offer the program under the BioCorRx model.

BioCorRx serves customers primarily through a network of licensed treatment providers and healthcare professionals in the United States. The company is headquartered in California. Lourdes Felix has served as BioCorRx’s chief executive officer and has been associated with the company’s development and expansion of its addiction-recovery programs.

View Biocorrx Profile
Earnings Tools